[Treatment of chronic aplastic anemia with securinine--analysis of 123 cases].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000009:adverse effects / Q000627:therapeutic use*; D000741:Anemia, Aplastic / Q000188:drug therapy*; D001381:Azepines; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002648:Child; D002908:Chronic Disease; D005260:Female; D006576:Heterocyclic Compounds, 4 or More Rings; D006572:Heterocyclic Compounds, Bridged-Ring; D006801:Humans; D007783:Lactones; D008297:Male; D008875:Middle Aged; D010880:Piperidines
D000470:Alkaloids; D001381:Azepines; D000697:Central Nervous System Stimulants; D006576:Heterocyclic Compounds, 4 or More Rings; D006572:Heterocyclic Compounds, Bridged-Ring; D007783:Lactones; D010880:Piperidines; C000785:securinine